Matches in SemOpenAlex for { <https://semopenalex.org/work/W145803218> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W145803218 abstract "Background & Objective: Regadenoson binds selectively to the A(2A) receptor to promote coronary vasodilation during stress testing. It is given as a fixed-dose rapid injection, thus simplifying the dosing regimen compared to adenosine and dipyridamole, obviating the need for an MRI compatible infusion pump. We assessed the safety and tolerability of regadenoson stress CMR. Materials & Methods: A group of 726 patients (age 57 ± 12, 56% males, 44% females, 20% diabetic (DM)) were prospectively recruited under an IRB-approved protocol with defined inclusion and exclusion criteria and scanned for clinical indications over a 30-month period. The control group consisted of 25 normal volunteers (age 23 ± 7). Patients were stressed with fixed dose regadenoson and scanned on a 1.5T scanner. Symptoms and major/minor adverse events including death, MI, arrhythmias, and hospitalization were assessed and recorded by the nurse and supervising physician. Results: Of the 726 exams, 99% (n=718) were of diagnostic quality. The most common symptoms in patients were dyspnea (30%, n=217), chest discomfort (28%, n=201), and headache (15%, n=111). Palpitations (60%, n=15) and dyspnea (28%, n=7) were common in the control group. Adverse events included bronchospasm (n=3, with one requiring hospitalization), symptomatic hypotension (n=1), contrast extravasation (n=2), and stress-induced SVT (n=1). Minor stress-induced arrhythmias (PVCs and PACs) occurred in 9% (n=67) of all exams. No VT/VF, death, MI, high grade AV block, or stress-induced atrial fibrillation occurred. There was no difference in SBP (p=0.60) and DBP (p=0.82) response, or rate pressure product (RPP) (p=0.33) between the patient vs. the control group. DM patients had a blunted heart rate (HR) response (p=0.002) when compared to non-DM patients despite a higher baseline HR (p=0.013), yet had no difference in SBP (p=0.30) and DBP (p=0.14) response, or RPP (p=0.20). Similarly, patients with abnormal perfusion exams had a blunted HR response (p=0.01), despite having a higher baseline HR (p Conclusions: Regadenoson CMR is well tolerated and can be performed safely with few adverse events. In diabetics and those with abnormal perfusion exams, a blunted HR response is noted." @default.
- W145803218 created "2016-06-24" @default.
- W145803218 creator A5049270829 @default.
- W145803218 creator A5056769337 @default.
- W145803218 creator A5059528272 @default.
- W145803218 creator A5060169945 @default.
- W145803218 creator A5066112448 @default.
- W145803218 creator A5075076342 @default.
- W145803218 date "2012-11-20" @default.
- W145803218 modified "2023-09-26" @default.
- W145803218 title "Abstract 17636: Safety and Tolerability of Regadenoson Stress CMR" @default.
- W145803218 hasPublicationYear "2012" @default.
- W145803218 type Work @default.
- W145803218 sameAs 145803218 @default.
- W145803218 citedByCount "0" @default.
- W145803218 crossrefType "journal-article" @default.
- W145803218 hasAuthorship W145803218A5049270829 @default.
- W145803218 hasAuthorship W145803218A5056769337 @default.
- W145803218 hasAuthorship W145803218A5059528272 @default.
- W145803218 hasAuthorship W145803218A5060169945 @default.
- W145803218 hasAuthorship W145803218A5066112448 @default.
- W145803218 hasAuthorship W145803218A5075076342 @default.
- W145803218 hasConcept C126322002 @default.
- W145803218 hasConcept C164705383 @default.
- W145803218 hasConcept C197934379 @default.
- W145803218 hasConcept C2776403943 @default.
- W145803218 hasConcept C2776890861 @default.
- W145803218 hasConcept C2777361974 @default.
- W145803218 hasConcept C2778213512 @default.
- W145803218 hasConcept C2778375690 @default.
- W145803218 hasConcept C2778405248 @default.
- W145803218 hasConcept C42219234 @default.
- W145803218 hasConcept C71924100 @default.
- W145803218 hasConceptScore W145803218C126322002 @default.
- W145803218 hasConceptScore W145803218C164705383 @default.
- W145803218 hasConceptScore W145803218C197934379 @default.
- W145803218 hasConceptScore W145803218C2776403943 @default.
- W145803218 hasConceptScore W145803218C2776890861 @default.
- W145803218 hasConceptScore W145803218C2777361974 @default.
- W145803218 hasConceptScore W145803218C2778213512 @default.
- W145803218 hasConceptScore W145803218C2778375690 @default.
- W145803218 hasConceptScore W145803218C2778405248 @default.
- W145803218 hasConceptScore W145803218C42219234 @default.
- W145803218 hasConceptScore W145803218C71924100 @default.
- W145803218 hasLocation W1458032181 @default.
- W145803218 hasOpenAccess W145803218 @default.
- W145803218 hasPrimaryLocation W1458032181 @default.
- W145803218 hasRelatedWork W1992378112 @default.
- W145803218 hasRelatedWork W2018785118 @default.
- W145803218 hasRelatedWork W2031649366 @default.
- W145803218 hasRelatedWork W2038205825 @default.
- W145803218 hasRelatedWork W2060585059 @default.
- W145803218 hasRelatedWork W2078436965 @default.
- W145803218 hasRelatedWork W2185245335 @default.
- W145803218 hasRelatedWork W2213150981 @default.
- W145803218 hasRelatedWork W2219833033 @default.
- W145803218 hasRelatedWork W2382847235 @default.
- W145803218 hasRelatedWork W2384368932 @default.
- W145803218 hasRelatedWork W2413358603 @default.
- W145803218 hasRelatedWork W2443690952 @default.
- W145803218 hasRelatedWork W2465247230 @default.
- W145803218 hasRelatedWork W2588384080 @default.
- W145803218 hasRelatedWork W2769171673 @default.
- W145803218 hasRelatedWork W3012292132 @default.
- W145803218 hasRelatedWork W3146469046 @default.
- W145803218 hasRelatedWork W3206922558 @default.
- W145803218 hasRelatedWork W35694326 @default.
- W145803218 hasVolume "126" @default.
- W145803218 isParatext "false" @default.
- W145803218 isRetracted "false" @default.
- W145803218 magId "145803218" @default.
- W145803218 workType "article" @default.